SAB Biotherapeutics completes first phase at production pharm

Oct. 24, 2018

SAB Biotherapeutics has completed the initial phase of an 80-acre production pharm near Canton.

The company will host a ribbon-cutting Oct. 30.

The state-of-the-art pharm is a highly specialized biosecure cattle facility designed to collect plasma to be used for the production of human biopharmaceuticals. SAB, founded in 2014, develops human immunotherapies using the company’s latest generation immunotherapy platform leveraging transgenic cattle, or TcBovine.

The TcBovine have been genetically designed to produce large amounts of human antibodies in response to a target disease. These antibodies are then purified for use as treatments for human diseases. SAB’s first two treatments are in clinical trials, with other autoimmune, oncology and infectious disease targets in development.

Phase 1 of the production pharm project includes a four-building complex with six employees caring for 80 animals. Phase 2, planned over a number of years, includes eight buildings, approximately 40 employees and 400 animals at full capacity.

The buildings are used for birthing and housing TcBovine with areas specifically designed for plasma collection, research, veterinary care, feed and equipment storage and offices.

Before their move to Lincoln County, SAB’s herd of transgenic cattle was housed at Trans Ova Genetics in Sioux Center, Iowa, and the related services were outsourced to Trans Ova’s team.

Moving the cattle closer to SAB’s headquarters in Sioux Falls has become a priority as the company continues to expand its operations to produce antibodies for additional disease targets. The proximity of the animals and internal team to the lab and production facility will improve efficiency and streamline operations while building production capacity for accelerated growth.

SAB Biotherapeutics to expand with 80-acre site

Want to stay in the know?

Get our free business news delivered to your inbox.



SAB Biotherapeutics completes first phase at production pharm

SAB Biotherapeutics has completed the initial phase of an 80-acre production pharm near Canton.

News Tip

Have a business news item to share with us?

Scroll to top